CN1882541B - N-[苯基(烷基-2-哌啶基)甲基]苯甲酰胺衍生物,其制备和治疗用途 - Google Patents

N-[苯基(烷基-2-哌啶基)甲基]苯甲酰胺衍生物,其制备和治疗用途 Download PDF

Info

Publication number
CN1882541B
CN1882541B CN200480033878XA CN200480033878A CN1882541B CN 1882541 B CN1882541 B CN 1882541B CN 200480033878X A CN200480033878X A CN 200480033878XA CN 200480033878 A CN200480033878 A CN 200480033878A CN 1882541 B CN1882541 B CN 1882541B
Authority
CN
China
Prior art keywords
methyl
phenyl
threo
piperidinyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200480033878XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1882541A (zh
Inventor
G·达加赞利
G·埃斯滕内-布托
C·韦罗尼克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Publication of CN1882541A publication Critical patent/CN1882541A/zh
Application granted granted Critical
Publication of CN1882541B publication Critical patent/CN1882541B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C07D211/28—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms to which a second hetero atom is attached
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN200480033878XA 2003-10-17 2004-10-15 N-[苯基(烷基-2-哌啶基)甲基]苯甲酰胺衍生物,其制备和治疗用途 Expired - Fee Related CN1882541B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0312141A FR2861071B1 (fr) 2003-10-17 2003-10-17 Derives de n-[phenyl(alkylpiperidin-2-yl) methyl]benzamide, leur prepartation et leur application en therapeutique
FR0312141 2003-10-17
PCT/FR2004/002642 WO2005037782A2 (fr) 2003-10-17 2004-10-15 Derives de n-[phenyl(alkylpiperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique

Publications (2)

Publication Number Publication Date
CN1882541A CN1882541A (zh) 2006-12-20
CN1882541B true CN1882541B (zh) 2011-07-06

Family

ID=34385234

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200480033878XA Expired - Fee Related CN1882541B (zh) 2003-10-17 2004-10-15 N-[苯基(烷基-2-哌啶基)甲基]苯甲酰胺衍生物,其制备和治疗用途

Country Status (26)

Country Link
US (1) US7790753B2 (OSRAM)
EP (1) EP1682503B1 (OSRAM)
JP (1) JP4754494B2 (OSRAM)
CN (1) CN1882541B (OSRAM)
AT (1) ATE359268T1 (OSRAM)
AU (1) AU2004281216B2 (OSRAM)
BR (1) BRPI0415433A (OSRAM)
CA (1) CA2542925A1 (OSRAM)
CY (1) CY1106653T1 (OSRAM)
DE (1) DE602004005886T2 (OSRAM)
DK (1) DK1682503T3 (OSRAM)
ES (1) ES2282916T3 (OSRAM)
FR (1) FR2861071B1 (OSRAM)
HR (1) HRP20070203T3 (OSRAM)
IL (1) IL174936A (OSRAM)
MA (1) MA28100A1 (OSRAM)
ME (1) MEP12708A (OSRAM)
NO (1) NO20062031L (OSRAM)
NZ (1) NZ547166A (OSRAM)
PL (1) PL1682503T3 (OSRAM)
PT (1) PT1682503E (OSRAM)
RS (1) RS20060317A (OSRAM)
RU (1) RU2351589C2 (OSRAM)
SI (1) SI1682503T1 (OSRAM)
WO (1) WO2005037782A2 (OSRAM)
ZA (1) ZA200603942B (OSRAM)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2842804B1 (fr) 2002-07-29 2004-09-03 Sanofi Synthelabo Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
FR2861074B1 (fr) * 2003-10-17 2006-04-07 Sanofi Synthelabo Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
PE20061156A1 (es) 2004-12-23 2006-12-16 Glaxo Group Ltd Derivados de benzamida como agentes inhibidores del transportador de glicina
GB0600427D0 (en) 2006-01-10 2006-02-15 Glaxo Group Ltd Compounds
US20100016374A1 (en) * 2006-04-05 2010-01-21 Steven Coulton Compounds Which Inhibit the Glycine Transporter and Uses Thereof
GB0612416D0 (en) * 2006-06-22 2006-08-02 Glaxo Group Ltd Compounds
US20110105602A2 (en) 2007-03-08 2011-05-05 Daria Mochly-Rosen Mitochondrial Aldehyde Dehydrogenase-2 Modulators and Methods of Use Thereof
WO2009013535A1 (en) * 2007-07-23 2009-01-29 Astrazeneca Ab 2-azabicyclo(2.2.2)octane derivatives as modulators of the glycine transporter i receptor
WO2009024611A2 (en) 2007-08-22 2009-02-26 Abbott Gmbh & Co. Kg 4-benzylaminoquinolines, pharmaceutical compositions containing them and their use
EP2271625B1 (en) 2008-04-01 2012-09-12 Abbott GmbH & Co. KG Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy
CN102209541B (zh) 2008-09-08 2016-05-18 小利兰·斯坦福大学托管委员会 醛脱氢酶活性调节剂和其使用方法
CN102202669A (zh) * 2008-10-28 2011-09-28 利兰·斯坦福青年大学托管委员会 醛脱氢酶调节剂及其使用方法
CA2746967A1 (en) * 2009-01-27 2010-08-05 F. Hoffmann-La Roche Ag Aroylamino - and heteroaroylamino-substituted piperidines as glyt-1 inhibitors
AR075182A1 (es) * 2009-01-28 2011-03-16 Astrazeneca Ab Compuestos 2-aza-biciclo (2.2.2) octano y sus usos
TW201038569A (en) 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
AR075442A1 (es) 2009-02-16 2011-03-30 Abbott Gmbh & Co Kg Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia
TW201036980A (en) * 2009-03-16 2010-10-16 Sanofi Aventis N-[(2-azabicyclo[2.1.1]hex-1-yl)(aryl)methyl]heteroben zamide derivatives, their preparation and their therapeutic application
FR2943056A1 (fr) * 2009-03-16 2010-09-17 Sanofi Aventis Derives de n-°2-aza-bicyclo°2.1.1!hex-1-yl)-aryl-methyl!- heterobenzamide, leur preparation et leur application en therapeutique
JP5618047B2 (ja) * 2010-01-29 2014-11-05 国立大学法人千葉大学 ポジトロン断層撮影法およびポジトロン放出化合物
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8846743B2 (en) 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9045459B2 (en) 2010-08-13 2015-06-02 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8877794B2 (en) 2010-08-13 2014-11-04 Abbott Laboratories Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2013020930A1 (en) 2011-08-05 2013-02-14 Abbott Gmbh & Co. Kg Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US8846741B2 (en) 2011-11-18 2014-09-30 Abbvie Inc. N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
CN105358531B (zh) 2013-03-14 2017-11-14 利兰-斯坦福大学初级学院的董事会 线粒体醛脱氢酶‑2调节剂和其使用方法
US9656955B2 (en) 2013-03-15 2017-05-23 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9650334B2 (en) 2013-03-15 2017-05-16 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
CN105764895A (zh) 2013-10-17 2016-07-13 艾伯维德国有限责任两合公司 氨基四氢化萘及氨基二氢化茚衍生物，包含其的药物组合物及其在治疗中的用途
CA2924689A1 (en) 2013-10-17 2015-04-23 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US9550754B2 (en) 2014-09-11 2017-01-24 AbbVie Deutschland GmbH & Co. KG 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3801636A (en) * 1971-08-13 1974-04-02 Abbott Lab 3,4,5-tri-substituted cinnamides
US5254569A (en) * 1991-01-14 1993-10-19 The Du Pont Merck Pharmaceutical Company (Amidomethyl)nitrogen heterocyclic analgesics
JP3026845B2 (ja) * 1991-02-20 2000-03-27 日清製粉株式会社 ピペリジン誘導体
CZ284456B6 (cs) 1992-02-15 1998-12-16 Hoechst Aktiengesellschaft Aminosubstituované benzoylguanidiny, způsob jejich přípravy, jejich použití jako léčiv a léčivo, které je obsahuje
EP1058684A1 (en) * 1998-03-06 2000-12-13 Janssen Pharmaceutica N.V. Glycine transport inhibitors
FR2838739B1 (fr) * 2002-04-19 2004-05-28 Sanofi Synthelabo Derives de n-[phenyl(piperidin-2-yl)methyl)benzamide, leur preparation et leur application en therapeutique
FR2842804B1 (fr) * 2002-07-29 2004-09-03 Sanofi Synthelabo Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
MXPA05006426A (es) * 2002-12-18 2005-09-08 Fmc Corp N-(arilmetil sustituido)-4-(metil disustituido) piperidina y piperazinas.
FR2861070B1 (fr) * 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-[phenyl(pyrrolidin-2-yl)methyl]benzamide et n-[(azepan-2-yl)phenylmethyl]benzamide, leur preparation et leur application en therapeutique
FR2861073B1 (fr) * 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-[heteroaryl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
FR2861076B1 (fr) * 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-heterocyclymethylbenzamide, leur preparation et leur application en therapeutique
WO2005080367A1 (en) * 2004-02-12 2005-09-01 Pharmagene Laboratories Limited Ep2 receptor agonists
US8492418B2 (en) * 2005-04-11 2013-07-23 Yale University Method of treating schizophrenia prodrome

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Olivier Froelich et. al..Asymmetric Synthesis. 39.1 Synthesis of2-(1-Aminoalkyl)piperidines via 2-Cyano-6-phenylOxazolopiperidine.J. Org. Chem.61 19.1996,61(19),6700-6705.
Olivier Froelich et. al..Asymmetric Synthesis. 39.1 Synthesis of2-(1-Aminoalkyl)piperidines via 2-Cyano-6-phenylOxazolopiperidine.J. Org. Chem.61 19.1996,61(19),6700-6705. *

Also Published As

Publication number Publication date
IL174936A (en) 2011-01-31
US20060223861A1 (en) 2006-10-05
CA2542925A1 (fr) 2005-04-28
WO2005037782A3 (fr) 2005-07-07
PL1682503T3 (pl) 2008-01-31
US7790753B2 (en) 2010-09-07
DK1682503T3 (da) 2007-07-16
MEP12708A (en) 2010-06-10
ES2282916T3 (es) 2007-10-16
AU2004281216B2 (en) 2010-07-22
BRPI0415433A (pt) 2006-12-05
IL174936A0 (en) 2006-08-20
SI1682503T1 (sl) 2007-08-31
WO2005037782A2 (fr) 2005-04-28
RS20060317A (sr) 2008-11-28
EP1682503B1 (fr) 2007-04-11
DE602004005886D1 (de) 2007-05-24
NZ547166A (en) 2009-11-27
CY1106653T1 (el) 2012-01-25
ZA200603942B (en) 2007-11-28
JP4754494B2 (ja) 2011-08-24
MA28100A1 (fr) 2006-08-01
AU2004281216A1 (en) 2005-04-28
DE602004005886T2 (de) 2008-01-17
EP1682503A2 (fr) 2006-07-26
FR2861071A1 (fr) 2005-04-22
RU2006116886A (ru) 2007-11-27
PT1682503E (pt) 2007-05-31
CN1882541A (zh) 2006-12-20
ATE359268T1 (de) 2007-05-15
RU2351589C2 (ru) 2009-04-10
FR2861071B1 (fr) 2006-01-06
JP2007508360A (ja) 2007-04-05
HRP20070203T3 (hr) 2007-06-30
NO20062031L (no) 2006-07-06

Similar Documents

Publication Publication Date Title
CN1882541B (zh) N-[苯基(烷基-2-哌啶基)甲基]苯甲酰胺衍生物,其制备和治疗用途
US7205319B2 (en) N-[phenyl (piperidin-2-yl) methyl]benzamide derivatives, preparation thereof, and use thereof in therapy
CN100482646C (zh) N-[苯基(哌啶-2-基)甲基]苯甲酰胺衍生物,其制备方法及其在治疗中的应用
CN100430394C (zh) N-[杂芳基(哌啶-2-基)甲基]苯甲酰胺衍生物及其制备方法和它们的治疗应用
CN1882540A (zh) N－[苯基(哌啶－2－基)甲基]苯甲酰胺衍生物、其制备以及其治疗用途
CN1882534A (zh) N－[苯基(2－吡咯烷基)甲基]苯甲酰胺和n－[(2－氮杂环庚烷基)苯基甲基]苯甲酰胺衍生物,其制备和治疗用途
CN102088855A (zh) 2-芳基甘氨酰胺衍生物
EP0718286B1 (en) 3-Alkoxybenzylpiperidine derivatives as melatonergic agents
NO172691B (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 4-fenyl-4-(n-(fenyl)amido)piperidinderivater
CN1210261C (zh) 具有5ht1a受体活性的芳基哌啶和芳基－1,2,5,6－四氢吡啶酰胺衍生物
HK1098141A (en) Derivatives of n-[phenyl(alkylpiperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics
CN1265658A (zh) 5－萘－1－基－1,3－二噁烷衍生物、它们的制备方法以及它们在治疗中的应用
KR20070019659A (ko) Ｎ-[페닐(알킬피페리딘-2-일)메틸]벤즈아미드 유도체, 그의제조 방법 및 그의 치료 용도
HK1030212A (en) 5-naphthalen-1-yl-1,3-dioxane derivatives, preparation and therapeutic application
HK1098456B (en) Derivatives of n-[heteroaryl(piperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics
JP2012107006A (ja) Ｎ−置換−環状アミノ誘導体の製造方法
HK1098143A (en) Derivatives of n-"phenyl(piperidine-2-yl) methyl benzamide, preparation method thereof and applications of same in therapeutics
JPWO2001070689A1 (ja) オピオイドδ受容体作用薬として有用なジフェニルアルキルアミン誘導体

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1098141

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1098141

Country of ref document: HK

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20110706

Termination date: 20121015